All In Biotech

Drug Trial Radar · NCT03875573

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

147

Actual

Start

Nov 6, 2019

Primary completion

Nov 30, 2024

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Jules Bordet InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut Curie; AstraZeneca
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1. the combination of weekly paclitaxel followed by dose-dense doxorubicin-cyclophosphamide (ddAC) and pre-operative radiation therapy (boost dose) on the primary tumour 2. arm 1 with the addition of the anti-PD-L1 antibody durvalumab 3. arm 2 with the addition of the anti-CD73 antibody oleclumab The primary tumour will be excised 2-6 weeks after completion of ddAC. A safety run-in is planned for the 6 first subjects before starting the randomized phase II trial. Those 6 subjects will receive the treatment given in Arm 3.

Conditions

  • Luminal B

Interventions

  • DurvalumabDrug

    an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.

  • Stereotactic Body RadiotherapyRadiation

    Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.

  • OleclumabDrug

    an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Run-in: Evaluation of the immune related or radiation therapy related toxicity of special interestTime frame: 7 months
  2. Safety Run-in: Evaluation of the feasibility of the primary surgeryTime frame: 7 months
  3. Phase II: Demonstration of the tumour response in arms 2 or 3 versus arm 1Time frame: 24 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitaire Ziekenhuizen

    Leuven, Belgium

  • CHU UCL Namur Sainte-Elisabeth

    Namur, Belgium

  • GZA - Ziekenhuizen (Campus St. Augustinus)

    Wilrijk, Belgium

  • Centre Georges François Leclerc

    Dijon, France

  • Institut Curie

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.